エーザイ、抗がん剤レンバチニブについてペムブロリズマブとの併用療法における進行性腎細胞がんおよび進行性子宮内膜がんに係る2つの適応追加申請が欧州医薬品庁により受理 Eisai Mar 30, 2021 10:00 JST Read More
Eisai: Discovery Research on AMPA-type Glutamate Receptor Antagonist Perampanel Honored With PSJ Award for Drug Research and Development 2021 Eisai Mar 26, 2021 08:16 HKT/SGT Read More
TrialWire launches StudyBoost, the Clinical Trial Insurance Plan TrialWire Mar 26, 2021 00:20 HKT/SGT Read More
Lenvima (Lenvatinib) Approved for Additional Indication of Unresectable Thymic Carcinoma in Japan Eisai Mar 23, 2021 17:34 HKT/SGT Read More
Eisai Begins Construction of Its New Injection/Research Building at Kawashima Industrial Park in Japan Eisai Mar 22, 2021 12:13 HKT/SGT Read More
Fujitsu Embarks on Joint Research with National Cancer Center Japan to Create New Services for Drug Development and Clinical Trials Fujitsu Ltd Mar 18, 2021 10:35 HKT/SGT Read More
Agilex Biolabs Showcases Advanced Immunoassay and Immunobiology Services at Bio-Europe Spring 2021 Agilex Biolabs Mar 17, 2021 17:00 JST Read More
DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders Eisai Mar 17, 2021 10:05 HKT/SGT Read More
Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer's Disease by Dian-Tu Eisai Mar 16, 2021 10:37 HKT/SGT Read More
エーザイ、DIAN-TUは優性遺伝アルツハイマー病に対する臨床試験において、抗MTBR（Microtubule binding region: 微小管結合領域）タウ抗体E2814を選定 Eisai Mar 16, 2021 09:00 JST Read More
Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer Eisai Mar 12, 2021 10:08 HKT/SGT Read More
エーザイ、抗がん剤「レンビマ(R)」（レンバチニブ）が日本において「予定される効能又は効果」としての子宮体がんについて、厚生労働省より希少疾病用医薬品に指定 Eisai Mar 12, 2021 09:00 JST Read More
Fujitsu, Kyoto University Develop Explainable AI Verification System for Estimating Disease-Causing Potential of Genetic Mutations Fujitsu Ltd Mar 11, 2021 12:22 HKT/SGT Read More
